Uremic Xerosis
Conditions
Brief summary
Among adult patients with chronic kidney disease undergoing hemodialysis, what is the efficacy and safety of virgin coconut oil compared to mineral oil as a therapeutic moisturizer for uremic xerosis?
Detailed description
Objectives of the Study: The general objective of this study is to assess the efficacy and safety of virgin coconut oil (VCO) compared to mineral oil as a therapeutic moisturizer for uremic xerosis. The specific objectives are as follows: 1) to determine and compare changes in the over-all dry skin score within and between treatment groups at baseline, 2 weeks-post and 4-weeks post application; 2) to quantitatively measure the following skin parameters at baseline, 2-weeks and 4-weeks post application (skin hydration using a corneometer, skin lipids using a sebumeter); 3) to determine and compare changes in quality of life scores within and between treatment groups at baseline, and 4-weeks post application; and 4) to identify the adverse effects of virgin coconut oil and mineral oil when used as moisturizer for uremic xerosis
Interventions
OTHERVirgin Coconut Oil
Virgin coconut oil applied to the test site twice daily for four weeks
OTHERMineral Oil
Mineral oil applied to the test site twice daily for four weeks
Sponsors
University of the Philippines
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Adults undergoing maintenance hemodialysis who have mild to severe uremic xerosis
Exclusion criteria
* Patients with known hypersensitivity to the tests oils were excluded from the study as well as patients with open wounds, erosions, and ulcers on the test site and paraplegics and patients with altered sensation on the test sites. * Patients with xerosis associated with other dermatologic conditions antedating renal failure were excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in baseline overall dry skin score | 4 weeks | — |
| Change in baseline corneometer readings | 4 weeks | Measurement of skin hydration |
| Change in baseline sebumeter readings | 4 weeks | Measurement of skin lipids |
Secondary
| Measure | Time frame |
|---|---|
| Change in Quality of life scores | 4 weeks |
| Patient-assessed efficacy | 4 weeks |
| Adverse events | 4 weeks |
Outcome results
None listed